Ethambutol optic neuropathy incidence 1.54 percent with renal impairment and hypertension as key risk factors
This is a systematic review and meta-analysis examining the incidence and risk factors of ethambutol optic neuropathy (EON), neuro-ophthalmic manifestations of tuberculous meningitis (TBM), and prognostic biomarkers for visual outcomes. The analysis included a total sample size of 260,430. The pooled incidence of EON was 1.54 percent (95% CI: 0.81-2.49 percent, I²=98.2 percent). Renal impairment was associated with an increased risk of EON (OR 3.73, 95% CI: 1.78-7.83), as was hypertension (OR 2.37, 95% CI: 1.46-3.84). In TBM, cranial nerve III palsy occurred in 17.4 percent of cases, papilledema in 12.5 percent, and optic atrophy in 16.7 percent. Hydrocephalus rates were higher in pediatric patients (72.5 percent) versus non-pediatric patients (13.0 percent), with a relative risk of 5.56. For subclinical changes, VEP demonstrated better detection than OCT (Hedges’ g difference: 0.686, P-value = 0.001). Visual recovery in clinical EON cases was 52.4 percent, with younger age and earlier ethambutol discontinuation associated with improved recovery. The authors note the high heterogeneity (I²=98.2 percent) as a limitation. Screening protocols targeting high-risk populations are recommended.